These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 10949910)
1. Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems. Jensen M; Hartmann T; Engvall B; Wang R; Uljon SN; Sennvik K; Näslund J; Muehlhauser F; Nordstedt C; Beyreuther K; Lannfelt L Mol Med; 2000 Apr; 6(4):291-302. PubMed ID: 10949910 [TBL] [Abstract][Full Text] [Related]
2. Generation and Partial Characterization of Rabbit Monoclonal Antibody to Amyloid-β Peptide 1-37 (Aβ37). Mehta PD; Blain JF; Freeman EA; Patrick BA; Barshatzky M; Hrdlicka LA; Mehta SP; Frackowiak J; Mazur-Kolecka B; Wegiel J; Patzke H; Miller DL J Alzheimers Dis; 2017; 57(1):135-145. PubMed ID: 28222530 [TBL] [Abstract][Full Text] [Related]
3. Reappraisal of Aβ40 and Aβ42 Peptides Measurements in Cerebrospinal Fluid of Patients with Alzheimer's Disease. Fiorini M; Bongianni M; Benedetti MD; Monaco S; Zanusso G J Alzheimers Dis; 2018; 66(1):219-227. PubMed ID: 30282368 [TBL] [Abstract][Full Text] [Related]
4. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays. Lewczuk P; Lelental N; Spitzer P; Maler JM; Kornhuber J J Alzheimers Dis; 2015; 43(1):183-91. PubMed ID: 25079805 [TBL] [Abstract][Full Text] [Related]
5. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration. Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689 [TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies against large oval aggregates of Aβ1-42. Shimizu T; Yoshimune K; Komoriya T; Akiyama T; Ye X; Kohno H J Biosci Bioeng; 2013 Feb; 115(2):216-20. PubMed ID: 23041139 [TBL] [Abstract][Full Text] [Related]
7. Generation and Partial Characterization of Rabbit Monoclonal Antibody to Pyroglutamate Amyloid-β3-42 (pE3-Aβ). Mehta PD; Patrick BA; Barshatzky M; Mehta SP; Frackowiak J; Mazur-Kolecka B; Wegiel J; Wisniewski T; Miller DL J Alzheimers Dis; 2018; 62(4):1635-1649. PubMed ID: 29504532 [TBL] [Abstract][Full Text] [Related]
10. Generation of Rabbit Monoclonal Antibody to Amyloid-β38 (Aβ38): Increased Plasma Aβ38 Levels in Down Syndrome. Mehta PD; Patrick BA; Barshatzky M; Mehta SP; Frackowiak J; Mazur-Kolecka B; Miller DL J Alzheimers Dis; 2015; 46(4):1021-32. PubMed ID: 26402629 [TBL] [Abstract][Full Text] [Related]
11. A new structural model of Alzheimer's Aβ42 fibrils based on electron paramagnetic resonance data and Rosetta modeling. Gu L; Tran J; Jiang L; Guo Z J Struct Biol; 2016 Apr; 194(1):61-7. PubMed ID: 26827680 [TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of the β-amyloid(4-10) epitope of plaque specific Aβ antibodies by affinity-mass spectrometry using alanine site mutation. Ștefănescu R; Lupu L; Manea M; Iacob RE; Przybylski M J Pept Sci; 2018 Jan; 24(1):. PubMed ID: 29322650 [TBL] [Abstract][Full Text] [Related]
13. Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort. Klafki HW; Hafermann H; Bauer C; Haussmann U; Kraus I; Schuchhardt J; Muck S; Scherbaum N; Wiltfang J J Alzheimers Dis; 2016 Sep; 54(2):691-705. PubMed ID: 27567847 [TBL] [Abstract][Full Text] [Related]
14. Development of homogeneous 384-well high-throughput screening assays for Abeta1-40 and Abeta1-42 using AlphaScreen technology. Szekeres PG; Leong K; Day TA; Kingston AE; Karran EH J Biomol Screen; 2008 Feb; 13(2):101-11. PubMed ID: 18216395 [TBL] [Abstract][Full Text] [Related]
16. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902 [TBL] [Abstract][Full Text] [Related]
17. Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies. Bogstedt A; Groves M; Tan K; Narwal R; McFarlane M; Höglund K J Alzheimers Dis; 2015; 46(4):1091-101. PubMed ID: 26402635 [TBL] [Abstract][Full Text] [Related]
18. New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF. Yang T; Hong S; O'Malley T; Sperling RA; Walsh DM; Selkoe DJ Alzheimers Dement; 2013 Mar; 9(2):99-112. PubMed ID: 23375565 [TBL] [Abstract][Full Text] [Related]
19. Quantification of Amyloid-β in Plasma by Simple and Highly Sensitive Immunoaffinity Enrichment and LC-MS/MS Assay. Iino T; Watanabe S; Yamashita K; Tamada E; Hasegawa T; Irino Y; Iwanaga S; Harada A; Noda K; Suto K; Yoshida T J Appl Lab Med; 2021 Jul; 6(4):834-845. PubMed ID: 33462584 [TBL] [Abstract][Full Text] [Related]
20. An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter. Lucey BP; Gonzales C; Das U; Li J; Siemers ER; Slemmon JR; Bateman RJ; Huang Y; Fox GB; Claassen JA; Slats D; Verbeek MM; Tong G; Soares H; Savage MJ; Kennedy M; Forman M; Sjögren M; Margolin R; Chen X; Farlow MR; Dean RA; Waring JF Alzheimers Res Ther; 2015; 7(1):53. PubMed ID: 26225140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]